Overview A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas Status: Recruiting Trial end date: 2024-12-30 Target enrollment: Participant gender: Summary This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas. Phase: Phase 1 Details Lead Sponsor: Antengene (Hangzhou) Biologics Co., Ltd.